MedTrace Logo

Evaluation of LDL Cholesterol in Patients Switched From 10 to 5 Milligrams of Zetia (Ezetimibe)

NCT00762229 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 39

Last updated 2013-06-14

Study results available
· View outcomes & findings →

Summary

The purpose of this study is to compare the effect on LDL cholesterol levels of converting patients who are receiving the cholesterol absorption inhibitor Zetia at a dose of 10 milligrams to 5 milligrams, when prescribed as a split 10 milligram tablet.

Conditions

Interventions

DRUG

Ezetimibe 10 mg

Ezetimibe 10 mg daily for 4 weeks

DRUG

Ezetimibe 5 mg

Ezetimibe 5 mg daily for 4 weeks, "formulated" as a 10 mg tablet split in half

Sponsors & Collaborators

  • Bronx VA Medical Center

    lead FED

Principal Investigators

  • Lawrence Baruch, MD · Bronx VA Medical Center

Study Design

Allocation
RANDOMIZED
Purpose
HEALTH_SERVICES_RESEARCH
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2007-07-31
Primary Completion
2008-09-30
Completion
2008-09-30

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00762229 on ClinicalTrials.gov